NASDAQ · ERYP

ERYTECH Pharma S.A.

Healthcare · Biotechnology

$0.78

Up+$0.01 (+1.30%)

Updated Oct 10, 2026, 12:40 PM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap: 47.38M
P/E ratio: -0.02
Dividend yield: 0.00%
52-week range: — – —
Volume: 3.21K
Avg. volume: 150.83K

Price performance · ERYP

ERYP price history

1M range · 0 trading sessions · Daily adjusted prices

Data unavailable

The requested market data was not found.

Latest ERYP news

The latest Smart Investors Daily articles mentioning ERYP.

No results

No recent SID articles mention ERYP.

Latest ERYP news

The latest Smart Investors Daily articles mentioning ERYP.

ERYP research

Overview

Company profile and research snapshot.

Company profile

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.

Visit company website